Table 2 Association of demographics and clinicopathological characteristics with BRAF mutation status in Cohort B.
From: Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
Characteristics | Wild type (n = 358) | BRAF mutation (n = 59) | P |
|---|---|---|---|
n (%) | n (%) | ||
Age (yrs.) | 0.31 | ||
≤65 | 237 (66.2) | 43 (72.9) | |
>65 | 121 (33.8) | 16 (27.1) | |
Gender | 0.36 | ||
Female | 89 (24.9) | 18 (30.5) | |
Male | 269 (75.1) | 41 (69.5) | |
Smoking status | 0.33 | ||
Never smoker | 128 (35.8) | 25 (42.4) | |
Former/current smoker | 230 (64.2) | 34 (57.6) | |
Stagea | 0.33 | ||
III | 19 (5.3) | 5 (8.5) | |
IV | 339 (94.7) | 54 (91.5) | |
ECOG PS | 0.25 | ||
0–1 | 331 (92.5) | 57 (96.6) | |
2 | 27 (7.5) | 2 (3.4) | |
Pathological type | 0.16 | ||
Adenocarcinoma | 315 (88.0) | 48 (81.4) | |
Other types | 43 (12.0) | 11 (18.6) | |
Treatment lines | 0.01 | ||
First line | 179 (50.0) | 40 (67.8) | |
Second/later line | 179 (50.0) | 19 (33.2) | |
Treatment regimens | 0.77 | ||
Monotherapy | 116 (32.4) | 18 (30.5) | |
Chemotherapy plus ICIs | 201 (56.1) | 37 (62.7) | |
Anti-angiogenesis plus ICIs | 41 (11.2) | 4 (6.8) | |
PD-L1 expression | 0.92b | ||
Negative | 33 (9.2) | 9 (15.3) | |
1–49% | 46 (12.8) | 14 (23.7) | |
≥50% | 31 (8.7) | 14 (23.7) | |
Unkonow | 248 (69.3) | 22 (37.3) |
